Sloan Simpson
Global Head of Investor Relations
All right. Hello, everyone and welcome to our 2025 Meet Novartis Management Investor Event. Thank you, as always, for your time, interest and engagement with us. This is a special event, which we’ve been doing for over 10 years because it allows investors and analysts to interact with our management teams in an open Q&A format. Today we’ll start with a presentation and a Q&A by Vas, followed by breakout sessions with our core therapeutic areas and corporate. The breakout sessions will be in a different room. So I’ll come back after Vas’s presentation to give directions and help you get where you need to be.
One other quick housekeeping note. For the Q&A after Vas’s presentation, we’ll have mic runners in the room. Please wait for the mic before asking your question so that we can ensure our webcast audience hears you clearly.
Before we get started, I’ll just read the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Please refer to the company’s Form 20-F on file with the U.S. Securities and Exchange Commission for a description of some of these
